Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 27;12:6902. doi: 10.1038/s41598-022-10914-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Integrated analyses from The Cancer Genome Atlas demonstrate that HML-6 envelope transcript, ERVK3-1, is a negative prognosticator in glioblastoma patients. (A) Across all samples, GBM patients with elevated ERVK3-1 expression had significantly lower median overall survival (17.9 months vs. 12.7 months, p = 0.018). (B) IDH-wild-type GBM patients with increased ERVK3-1 expression (> 3.3 FPKM) have a worse OS (17.9 vs. 12.9 months, p = 0.028). Analysis of CGGA data demonstrated significantly lower overall survival in patients with elevated ERVK3-1 expression, in all patients (median OS = 10 months vs. 19.4 months, p = 0.018) (C). Among IDHwt patients alone, a similar trend was seen, though these differences were non-significant (median OS = 12.2 months vs. 11.3 months, p = 0.055) (D). In addition, patients with IDH mutant GBM had significantly lower ERVK3-1 expression relative to patients with IDHwt tumors (4.57 fpkm vs. 5.19 fpkm, p < 0.0001) (E), as did patients with 1p19q co-deletion (4.41 fpkm vs. 5.17 fpkm, p < 0.0001) (F). (G) Analysis of ERVK3-1 expression by GBM subtype revealed that the classical subtype has significantly higher ERVK3-1 expression than both mesenchymal glioblastomas and IDHm gliomas.